{"id":29346,"date":"2025-09-13T19:05:15","date_gmt":"2025-09-13T19:05:15","guid":{"rendered":"https:\/\/www.europesays.com\/se\/29346\/"},"modified":"2025-09-13T19:05:15","modified_gmt":"2025-09-13T19:05:15","slug":"astra-zeneca-pausar-brittisk-miljardinvestering","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/29346\/","title":{"rendered":"Astra Zeneca pausar brittisk miljardinvestering"},"content":{"rendered":"<p>L\u00e4kemedelsj\u00e4tten Astra Zeneca pausar sin investering i bolagets forskningscenter i Cambridge i Storbritannien, rapporterar CNBC. <\/p>\n<p>Satsningen skulle kosta 200 miljoner pund, motsvarande 2,7 miljarder kronor, och v\u00e4ntades ge 1000 nya jobb. <\/p>\n<p>Beskedet kommer strax inp\u00e5 att den amerikanska rivalen Merck gett beskedet att man avbryter satsningen p\u00e5 ett nytt forskningscenter i London p\u00e5 grund av det \u201dutmanande aff\u00e4rsklimatet i London\u201d. <\/p>\n<p>Tidigare i \u00e5r stoppade bolaget \u00e4ven bygget av en ny vaccinfabrik i norra England som v\u00e4ntades kosta 450 miljoner pund, efter minskat st\u00f6d fr\u00e5n den brittiska regeringen.<\/p>\n<p>Omni \u00e4r politiskt obundna och oberoende. Vi str\u00e4var efter att ge fler perspektiv p\u00e5 nyheterna. Har du fr\u00e5gor eller synpunkter kring v\u00e5r rapportering? <a href=\"https:\/\/omni.se\/astra-zeneca-pausar-brittisk-miljardinvestering\/a\/mailto:redaktion@omni.se\" class=\"ArticleActions_contactLink__W2F1M\" rel=\"nofollow noopener\" target=\"_blank\">Kontakta redaktionen<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"L\u00e4kemedelsj\u00e4tten Astra Zeneca pausar sin investering i bolagets forskningscenter i Cambridge i Storbritannien, rapporterar CNBC. Satsningen skulle kosta&hellip;\n","protected":false},"author":2,"featured_media":29347,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[65],"tags":[2957,72,70,71,538,2958,34,31,33,32,30],"class_list":{"0":"post-29346","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-ekonomi","8":"tag-astra-zeneca","9":"tag-business","10":"tag-economy","11":"tag-ekonomi","12":"tag-lakemedel-medicinteknik","13":"tag-lakemedelsindustri","14":"tag-se","15":"tag-svenska","16":"tag-sverige","17":"tag-sweden","18":"tag-swedish"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/29346","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=29346"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/29346\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/29347"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=29346"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=29346"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=29346"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}